Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Influenza Vaccine
NCT01481454Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2012
- Primary completion
- Oct 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Percentage of participants reporting solicited injection site reactions and solicited systemic reactions and Percentage of participants reporting unsolicited systemic reactions including serious adverse events (SAE). Started Mar 2012; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01481454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481454.